Treatment of Behcet’s disease
DOI:
https://doi.org/10.22122/cdj.v1i1.20Keywords:
Behcet’s Disease, Treatment, Manifestation, DiagnosisAbstract
Behcet’s disease is a systemic disease classified among vasculitides. Major manifestations are mucous membrane lesions (oral aphthosis and genital aphthosis), skin manifestations (pseudofolliculitis, erythema nodosum), ocular manifestations (uveitis, retinal vasculitis), joint manifestations, vascular lesions (small to large vessel thrombosis, aneurysm), gastrointestinal manifestations, orchiepididymitis, and some rare manifestations like cardiac, pulmonary, and renal impairment. Diagnosis is mainly clinical. The International Diagnosis Criteria for Behcet’s Disease may be of help. The gold standard of treatment for mucocutaneous lesions is colchicine. In refractory cases, levamisole, thalidomide, and dapsone may be of help. For major organ involvement like the eyes and the brain, immunosuppressive drugs and prednisolone are the gold standard. In refractory cases, biological agents are the last resort. For gastrointestinal manifestations, sulfasalazine and prednisolone are the first-line treatment. For vascular involvement, the first line treatment was anticoagulation, but recently it was shown that immunosuppressive drugs and prednisolone were confirmed to be the best. In all refractory cases and for all different organs, the last resort is biological agents.
References
Davatchi F. Behcet's disease. In: Howe HS, Feng PH, editors. Textbook of clinical rheumatology. Singapore, Singapore: National Arthritis Foundation; 1997. p. 298-315.
Davatchi F. Behcet's disease. In: Syngle A, editor. Rheumatology: principles and practice. London, UK: Jp Medical Pub; 2009. p. 249-68.
Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, et al. Behcet's disease: from East to West. Clin Rheumatol 2010; 29(8): 823-33.
Davatchi F, Shahram F, Akbarian M, Hatef MR, Chams C. Epidemiology of Behcet's disease in Iran. In: Nasution AR, Darmawan H, Isbagio H, editors. Rheumatology: APLAR. London, UK: Churchill Livingstone; 1992.
Davatchi F, Shahram F, Kumar A, Cheng YK, Cheong CT, Bendrups A. Comparative analysis of Behcet's disease in the APLAR region. APLAR Journal of Rheumatology 2004; 7(1): 38-43.
Chamberlain MA. Behcet's syndrome in 32 patients in Yorkshire. Ann Rheum Dis 1977; 36(6): 491-9.
Davatchi F, Shahram F. Epidemiology of Behcet's disease in Middle East and Asia. In: Lee S, Bang D, Lee ES, Editors. Behçet's Disease: A guide to its clinical understanding: textbook and atlas. Berlin, Germany: Springer; 2000. p. 581-3.
Zouboulis CC. Epidemiology of adamantiades-Behcet's Disease. In: Zierhut M, Ohno S, editors. Immunology of Behçet's disease. New York, NY: Taylor & Francis; 2003. p. 1-16.
Kaneko F, Nakamura K, Sato M, Tojo M, Zheng X, Zhang JZ. Epidemiology of Behcet's disease in Asian countries and Japan. Adv Exp Med Biol 2003; 528: 25-9.
Mahr A, Belarbi L, Wechsler B, Jeanneret D, Dhote R, Fain O, et al. Population-based prevalence study of Behcet's disease: differences by ethnic origin and low variation by age at immigration. Arthritis Rheum 2008; 58(12): 3951-9.
O'Duffy JD. Behcet's syndrome. N Engl J Med 1990; 322(5): 326-8.
Shahram F, Davatchi F, Nadji A, Jamshidi A, Chams H, Chams C, et al. Recent epidemiological data on Behcet's disease in Iran. The 2001 survey. Adv Exp Med Biol 2003; 528: 31-6.
Davatchi F, Jamshidi AR, Tehrani Banihashemi A, Forouzanfar MH, Moradi M, Akhlaghi M, et al. Prevalence of Behcet's disease in Iran: a WHO-ILAR COPCORD stage I study. APLAR Journal of Rheumatology 2007; 10(3): 239-43.
Davatchi F, Jamshidi AR, Banihashemi AT, Gholami J, Forouzanfar MH, Akhlaghi M, et al. WHO-ILAR COPCORD Study (Stage 1, Urban Study) in Iran. J Rheumatol 2008; 35(7): 1384.
Calamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM. Epidemiology and clinical characteristics of Behcet's disease in the US: a population-based study. Arthritis Rheum 2009; 61(5): 600-4.
Bang D, Lee JH, Lee ES, Lee S, Choi JS, Kim YK, et al. Epidemiologic and clinical survey of Behcet's disease in Korea: the first multicenter study. J Korean Med Sci 2001; 16(5): 615-8.
al-Dalaan AN, al Balaa SR, el Ramahi K, al-Kawi Z, Bohlega S, Bahabri S, et al. Behcet's disease in Saudi Arabia. J Rheumatol 1994; 21(4): 658-61.
Berrah A, Remache A, Ouadahi N. Clinical manifestations of Behcet's disease. analysis of 58 cases. In: Lee S, Bang D, Lee ES, Editors. Behçet's Disease: A guide to its clinical understanding: textbook and atlas. Berlin, Germany: Springer; 2000. p. 77-82.
Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, et al. Behcet's disease in Iran: analysis of 6500 cases. Int J Rheum Dis 2010; 13(4): 367-73.
Benezra D, Cohen E. Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol 1986; 70(8): 589-92.
Davatchi F, Shams H, Shahram F, Nadji AH, Jamshidi AR, Akhlaghi M, et al. Management of ocular manifestations of Behcet's disease: outcome with cytotoxic drugs. APLAR Journal of Rheumatology 2005; 8(2): 119-23.
Mizushima Y, Matsumura N, Mori M, Shimizu T, Fukushima B, Mimura Y, et al. Timing of cyclosporin-A therapy for abrogation of HVG and GVH responses in rats. Lancet 1977; 2(8046): 1037.
Haim S, Friedman-Birnbaum R. Colchicine in Behcet's disease. Harefuah 1977; 93(12): 399-400.
Aktulga E, Altac M, Muftuoglu A, Ozyazgan Y, Pazarli H, Tuzun Y, et al. A double blind study of colchicine in Behcet's disease. Haematologica 1980; 65(3): 399-402.
Yurdakul S, Mat C, Tuzun Y, Ozyazgan Y, Hamuryudan V, Uysal O, et al. A double-blind trial of colchicine in Behcet's syndrome. Arthritis Rheum 2001; 44(11): 2686-92.
Hazen PG, Michel B. Management of necrotizing vasculitis with colchicine. Improvement in patients with cutaneous lesions and Behcet's syndrome. Arch Dermatol 1979; 115(11): 1303-6.
Raynor A, Askari AD. Behcet's disease and treatment with colchicine. J Am Acad Dermatol 1980; 2(5): 396-400.
Miyachi Y, Taniguchi S, Ozaki M, Horio T. Colchicine in the treatment of the cutaneous manifestations of Behcet's disease. Br J Dermatol 1981; 104(1): 67-9.
Moreno MJ, Estrada Saiz RV, Chantres Antoranz MT, Rivas FJ, Gilsanz GV. Therapeutic value of colchicine in Behchet's disease (author's transl). Med Clin (Barc) 1981; 77(1): 18-20. [In Spanish].
Harper RM, Allen BS. Use of colchicine in the treatment of Behcet's disease. Int J Dermatol 1982; 21(9): 551-4.
Sander HM, Randle HW. Use of colchicine in Behcet's syndrome. Cutis 1986; 37(5): 344-8.
Davatchi F, Jamshidi AR, Tehrani BA, Gholami J, Hossein FM, Akhlaghi M, et al. Effect of ethnic origin (Caucasians versus Turks) on the prevalence of rheumatic diseases: a WHO-ILAR COPCORD urban study in Iran. Clin Rheumatol 2009; 28(11): 1275-82.
Hamza M, Ben AH. Treatment of Behcet disease with levamisole. Tunis Med 1979; 57(1): 17-9.
de Merieux P, Spitler LE, Paulus HE. Treatment of Behcet's syndrome with levamisole. Arthritis Rheum 1981; 24(1): 64-70.
Hamza M, Ayed K, Ben AH. Treatment of Behcet's disease with levamisole. Arthritis Rheum 1982; 25(6): 714-5.
Davatchi F, Baygan F, Chams H, Chams C, Contractor M. Levamisol in the treatment of Behcet's Disease. Proceedings of the Xth European Congress of Rheumatology; 1983 June-July; Moscow, Russia. p. 363.
Davatchi F, Shahram F, Chams-Davatchi C, Shams H, Nadji A, Akhlaghi M, et al. How to deal with Behcet's disease in daily practice. Int J Rheum Dis 2010; 13(2): 105-16.
Sun A, Wang YP, Chia JS, Liu BY, Chiang CP. Treatment with levamisole and colchicine can result in a significant reduction of IL-6, IL-8 or TNF-alpha level in patients with mucocutaneous type of Behcet's disease. J Oral Pathol Med 2009; 38(5): 401-5.
Hamza MH. Treatment of Behcet's disease with thalidomide. Clin Rheumatol 1986; 5(3): 365-71.
Denman AM, Graham E, Howe L, Denman EJ, Lightman S. Low dose thalidomide treatment of Behcet's syndrome. In: Godeau P, Wechsler B, editors. Behcet's disease. Amsterdam, The Netherlands: Elsevier Science Publishers B.V; 1993.
Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994; 53(12): 828-32.
Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S, et al. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128(6): 443-50.
Sayarlioglu M, Kotan MC, Topcu N, Bayram I, Arslanturk H, Gul A. Treatment of recurrent perforating intestinal ulcers with thalidomide in Behcet's disease. Ann Pharmacother 2004; 38(5): 808-11.
Direskeneli H, Ergun T, Yavuz S, Hamuryudan V, Eksioglu-Demiralp E. Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease. Clin Rheumatol 2008; 27(3): 373-5.
Sharquie KE. Suppression of Behcet's disease with dapsone. Br J Dermatol 1984; 110(4): 493-4.
Hamza M, Hamzaoui K, Ayed K. Treatment of Behcet's disease with dapsone. Clin Rheumatol 1989; 8(1): 113-4.
Joshi A, Mamta. Behcet's syndrome with pyoderma-gangrenosum-like lesions treated successfully with dapsone monotherapy. J Dermatol 2004; 31(10): 806-10.
Wechsler B, Le Thi Huong DU, Godeau P. Medical treatment of Behcet's disease. J Mal Vasc 1988; 13(3): 262-9.
De Bast C. Behcet's syndrome: treatment with prednisolone-cyclophosphamide association. Arch Belg Dermatol Syphiligr 1971; 27(3): 299-304. [In French].
Davatchi F, Baygan F, Chams H, Chams C. Cyclophosphamide in the treatment of the ocular manifestations of Behcet's disease. J Rheumatol 1984; 11(3): 404-5.
Davatchi F, Chams H, Shahram F, Akbarian M, Hatef MR, Chams C. Pulse cyclophosphamide in ophthalmologic manifestations of Behcet's Disease. In: Ferraz de Oliveira LN, Editor. Ophthalmology today. Amsterdam, The Netherlands: Excerpta Medica; 1988. p. 387-91.
Davatchi F, Shahram F, Chams H, Chams C, Akbarian M, Hatef MR, et al. Pulse cyclophosphamide in ophthalmological manifestations of Behcet's disease. In: O'Duffy JD, Kokmen E, editors. Behcet's disease: basic and clinical aspects. New York, NY: M. Dekker; 1991. p. 555-61.
Fain O, Thi Huong Du L, Wechsler B, Cochereau I, Le Huong P, Souillem J, et al. Pulse cyclophosphamide in Behcet's Disease. In: O'Duffy JD, Kokmen E, editors. Behcet's disease: basic and clinical aspects. New York, NY: M. Dekker, 1991. p. 569-73.
Hamza M, Meddeb S, Mili I, Ouertani A. Bolus of cyclophosphamide and methylprednisolone in uveitis in Behcet's disease. Preliminary results with the use of new criteria of evaluation. Ann Med Interne (Paris) 1992; 143(7): 438-41. [In French].
Shahram F, Davatchi F, Chams H, Akbarian M, Gharibdoost F. Low dose pulse cyclophosphamide (LDP) in ophthalmologic lesions of Behcet's Disease. In: Godeau P, Wechsler B, editors. Behcet's disease. Amsterdamn, The Netherlands: Elsevier Science Publishers B.V; 1993. p. 683-6.
Davatchi F, Shahram F, Chams H, Akbarian M, Nadji A, Gharibdoost F, et al. Pulse cyclophosphamide for ocular manifestations of Behcet's disease. Cohort study on 283 patients. Rev Rheum (Engl Ed) 1998; 65: 692.
Davatchi F, Shahram F, Chams H, Akbarian M. Pulse cyclophosphamide in ocular manifestations of Behcet's Disease: a double blind controlled crossover study. Arch Iranian Med 2004; 7(3): 201-5.
Davatchi F, Shahram F, Chams H, Nadji A, Jamshidi AR, Chams C, et al. Cytotoxic drugs in ocular lesions of Behçet's disease. Arthritis Res Ther 2003; 5(Suppl 2): 3.
Davatchi F. Treatment of ocular manifestations of Behcet's disease. Adv Exp Med Biol 2003; 528: 487-91.
Mamo JG, Azzam SA. Treatment of Behcet's disease with chlorambucil. Arch Ophthalmol 1970; 84(4): 446-50.
Davatchi F, Chams H, Shahram F, Nadji A, Chams-Davatchi C, Sadeghi-Abdollahi B, et al. Longitudinal study of chlorambucil in ocular manifestations of Behçet's disease. Iranian Journal of Ophthalmology 2009; 21(1): 3-14.
Rosselet E, Saudan Y, Zenklusen G. Effects of azathioprine ("Imuran") in Behcet's disease. Preliminary therapeutic results. Ophthalmologica 1968; 156(3): 218-26.
Jordano J, Pena JF, Abu-Yaghi EN. Response to the heparin-azothioprine combination in a case of uveitis of the hypopion (Behcet) initially worsened by corticosteroids. Rev Clin Esp 1974; 132(2): 177-80.
Aoki K, Sugiura S. Immunosuppressive treatment of Behcet's disease. Mod Probl Ophthalmol 1976; 16: 309-13.
Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med 1990; 322(5): 281-5.
Davatchi F, Shahram F, Chams H, Akbarian M, Nadji A, Chams C, et al. Azathioprine for the treatment of ophthalmological lesions of Behcet's Disease. In: Lee S, Bang D, Lee ES, editors. Behçet's disease: a guide to its clinical understanding: textbook and atlas.Berlin, Germany: Springer; 2000. p. 898-900.
Saadoun D, Wechsler B, Terrada C, Hajage D, Le Thi HD, Resche-Rigon M, et al. Azathioprine in severe uveitis of Behcet's disease. Arthritis Care Res (Hoboken) 2010; 62(12): 1733-8.
Shahram F, Davatchi F, Chams H, Akbarian M, Chams C, Tebbi ME. Methotrexate in ocular Behcet. Preliminary report. Disease. Proceedings of the 1st APLAR Symposium on the Therapy of Rheumatic Diseases. Abstract FP-23; 1990 Nov; Seoul, Korea.
Davatchi F, Shahram F, Chams H, Jamshidi AR, Nadji A, Chams C, et al. Methotrexate for ocular lesions of Behcet's Disease. Cohort study on 262 patients. Arthritis Rheum 1998; 41: S356.
Davatchi F, Shahram F, Chams H, Jamshidi AR, Nadji A, Chams C, et al. High dose methotrexate for ocular lesions of Behcet's disease. Preliminary short-term results. Adv Exp Med Biol 2003; 528: 579-84.
Davatchi F, Shahram F, Shams H. Proceedings of the 14th International Conference on Behcet's Disease; 2010 Jul 8-10; London, UK.
Nussenblatt RB, Palestine AG, Chan CC, Mochizuki M, Yancey K. Effectiveness of cyclosporin therapy for Behcet's disease. Arthritis Rheum 1985; 28(6): 671-9.
Whitcup SM, Salvo EC, Nussenblatt RB. Combined cyclosporine and corticosteroid therapy for sight-threatening uveitis in Behcet's disease. Am J Ophthalmol 1994; 118(1): 39-45.
Fujino Y, Joko S, Masuda K, Yagi I, Kogure M, Sakai J, et al. Ciclosporin microemulsion preconcentrate treatment of patients with Behcet's disease. Jpn J Ophthalmol 1999; 43(4): 318-26.
Chams-Davatchi C, Shizarpour M, Davatchi F, Shahram F, Chams H, Nadji A, et al. Extensive pyoderma gangrenosum-like lesion in two cases of Behcet's disease, responding only to cyclosporin. Adv Exp Med Biol 2003; 528: 337-8.
Kim DW, Lee BI, Park SH. Accelerated healing of pyoderma gangrenosum in Behcet patient treated with cyclosporine and split thickness skin graft. Ann Plast Surg 2008; 61(5): 552-4.
Vikas A, Atul S, Singh R, Sarbmeet L, Mohan H. Behçet disease with relapsing cutaneous polyarteritis nodosa-like lesions, responsive to oral cyclosporine therapy. Dermatology Online Journal 2003; 9(5): 9.
Ahn JK, Park YG, Park SW, Yoon KC, Yu HG, Chung H. Combined low dose cyclosporine and prednisone down-regulate natural killer cell-like effector functions of CD8brightCD56+ T cells in patients with active Behcet uveitis. Ocul Immunol Inflamm 2006; 14(5): 267-75.
Akman-Demir G, Ayranci O, Kurtuncu M, Vanli EN, Mutlu M, Tugal-Tutkun I. Cyclosporine for Behcet's uveitis: is it associated with an increased risk of neurological involvement? Clin Exp Rheumatol 2008; 26(4 Suppl 50): S84-S90.
Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol 2010; 94(3): 284-8.
Zaghetto JM, Yamamoto MM, Souza MB, Silva FT, Hirata CE, Olivalves E, et al. Chlorambucil and cyclosporine A in Brazilian patients with Behcet's disease uveitis: a retrospective study. Arq Bras Oftalmol 2010; 73(1): 40-6.
Chi W, Yang P, Zhu X, Wang Y, Chen L, Huang X, et al. Production of interleukin-17 in Behcet's disease is inhibited by cyclosporin A. Mol Vis 2010; 16: 880-6.
Saricaoglu H, Bulbul EB, Cikman ST, Dilek K, Tunali S. Effects of long-term cyclosporine A therapy on renal functions in Behcet's disease. Int J Tissue React 2004; 26(3-4): 93-6.
Riera-Mestre A, Martinez-Yelamos S, Martinez-Yelamos A, Vidaller A, Pujol R. Neuro-Behcet and neurotoxicity due to cyclosporine. Rev Clin Esp 2008; 208(4): 205-6.
Bouomrani S, Hammami S, Braham R, Mahjoub S. Ciclosporin-associated cerebral tumor-like location of Behcet's disease. Rev Neurol (Paris) 2010; 166(10): 849-54. [In French].
Shahram F, Davatchi F, Chams H, Akbarian M, Chams C. Pulse cyclophosphamide versus pulse methotrexate in ophthalmological manifestations of Behcet’s Disease. In: Nasution AR, Darmawan H, Isbagio H, editors. Rheumatology: APLAR. London, UK: Churchill Livingstone; 1992.
Martin M, Gil H, Hafsaoui C, Meaux-Ruault N, Magy-Bertrand N. Role of cyclosporine in the occurrence of neuro-Behcet's disease?. Rev Med Interne 2010; 31(11): e7-e8.
Gharibdoost F, Davatchi F, Chams H, Akbarian M. Comparing three methods of cytotoxic therapy in ophthalmologic lesions of Behcet's disease. In: Godeau P, Wechsler B, editors. Behcet's disease. Amsterdam, The Netherlands: Elsevier Science Publishers B.V; 1993.
Shahram F. Treatment of ophthalmological lesions of Behcet's disease. Proceedings of the 2nd APLAR Symposium on the Therapy of Rheumatic Diseases; 1994 Dec 4-8; Kuala Lumpur, Malaysia. p. 32.
Davatchi F. Management of Behcet's Disease. Proceedings of the International Conferences of Ophthalmology; 2010 Feb 17-19; Tehran, Iran.
Tsambaos D, Eichelberg D, Goos M. Behcet's syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986; 278(4): 335-6.
Kotter I, Gunaydin I, Treusch M, Zierhut M, Kanz L, Stubiger N. The use of interferon-alpha in Behcet's disease-review of the literature and possible mechanisms of action. Adv Exp Med Biol 2003; 528: 503-9.
Aral A, Onder M, Gurer MA. A case of Behcet's disease with pathergy reaction at interferon injection site. Adv Exp Med Biol 2003; 528: 541-3.
Kotter I, Zierhut M, Eckstein A, Vonthein R, Ness T, Gunaydin I, et al. Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behcet's disease with sight-threatening retinal vasculitis. Adv Exp Med Biol 2003; 528: 521-3.
Deuter CM, Koetter I, Guenaydin I, Stuebiger N, Zierhut M. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 2006; 26(7): 786-91.
Krause L, Altenburg A, Pleyer U, Kohler AK, Zouboulis CC, Foerster MH. Longterm visual prognosis of patients with ocular Adamantiades-Behcet's disease treated with interferon-alpha-2a. J Rheumatol 2008; 35(5): 896-903.
Gueudry J, Wechsler B, Terrada C, Gendron G, Cassoux N, Fardeau C, et al. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet disease. Am J Ophthalmol 2008; 146(6): 837-44.
Boyvat A, Sisman-Solak C, Gurler A. Long-term effects of interferon alpha 2A treatment in Behcet's disease. Dermatology 2000; 201(1): 40-3.
O'Duffy JD, Calamia K, Cohen S, Goronzy JJ, Herman D, Jorizzo J, et al. Interferon-alpha treatment of Behcet's disease. J Rheumatol 1998; 25(10): 1938-44.
Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Yurdakul S, Hamuryudan V, et al. Etanercept is beneficial in controlling the mucocutaneous lesions of Behçet's syndrome (BS) at short term but does not suppress the pathergy reaction and the cutaneous response to intradermally injected monosodium urate (MSU) crystals: a double blind placebo controlled trial. Arthritis Rheum 2002; 46(Suppl): S206.
Melikoglu M, Ozyazgan Y, Fresko I. The response of treatment resistant uveitis in Behcet's syndrome (BS) to a TNF-alpha blocker, etanercept: an open study. Arthritis Rheum 2002; 46(Suppl): S181.
Sablé-Fourtassou R, Wechsler B, Bodaghi B, Cassoux N, LeFloang P, Piette JC. Infliximab in refractory panuveitis due to Behcet's disease. Proceedings of the 10th International Conference on Behçet's Disease; 2002 Jun 27-29; Berlin, Germany.
Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN. Effect of infliximab on sight-threatening panuveitis in Behcet's disease. Lancet 2001; 358(9278): 295-6.
Tabbara KF, Al-Hemidan AI. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behcet disease. Am J Ophthalmol 2008; 146(6): 845-50.
Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease. Ann Intern Med 2004; 140(5): 404-6.
Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behcet's disease with refractory uveoretinitis. J Rheumatol 2004; 31(7): 1362-8.
Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behcet's disease: an open-label trial. Arthritis Rheum 2005; 52(8): 2478-84.
Niccoli L, Nannini C, Benucci M, Chindamo D, Cassara E, Salvarani C, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study. Rheumatology (Oxford) 2007; 46(7): 1161-4.
Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P. Infliximab treatment for ocular and extraocular manifestations of Behcet's disease. Jpn J Ophthalmol 2007; 51(3): 191-6.
Al-Rayes H, Al-Swailem R, Al-Balawi M, Al-Dohayan N, Al-Zaidi S, Tariq M. Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial. Rheumatol Int 2008; 29(1): 53-7.
Iwata S, Saito K, Yamaoka K, Tsujimura S, Nawata M, Suzuki K, et al. Effects of anti-TNF-alpha antibody infliximab in refractory entero-Behcet's disease. Rheumatology (Oxford) 2009; 48(8): 1012-3.
Giardina A, Ferrante A, Ciccia F, Vadala M, Giardina E, Triolo G. One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behcet's disease refractory to standard immunosuppressive drugs. Rheumatol Int 2011; 31(1): 33-7.
Tanaka H, Sugita S, Yamada Y, Kawaguchi T, Iwanaga Y, Kamoi K, et al. Effects and safety of infliximab administration in refractory uveoretinitis with Behcet's disease. Nihon Ganka Gakkai Zasshi 2010; 114(2): 87-95.
Mussack T, Landauer N, Ladurner R, Schiemann U, Goetzberger M, Burchardi C, et al. Successful treatment of cervical esophageal perforation in Behcet's disease with drainage operation and infliximab. Am J Gastroenterol 2003; 98(3): 703-4.
Kram MT, May LD, Goodman S, Molinas S. Behcet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case. Dis Colon Rectum 2003; 46(1): 118-21.
Hassard PV, Binder SW, Nelson V, Vasiliauskas EA. Anti-tumor necrosis factor monoclonal antibody therapy for gastrointestinal Behcet's disease: a case report. Gastroenterology 2001; 120(4): 995-9.
Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients. Semin Arthritis Rheum 2011; 41(1): 61-70.
Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22(47): 7359-68.
Kneitz C, Wilhelm M, Tony HP. Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 2002; 206(5): 519-27.
Sadreddini S, Noshad H, Molaeefard M, Noshad R. Treatment of retinal vasculitis in Behcet's disease with rituximab. Mod Rheumatol 2008; 18(3): 306-8.
Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A, et al. Rituximab in intractable ocular lesions of Behcet's disease; randomized single-blind control study (pilot study). Int J Rheum Dis 2010; 13(3): 246-52.
Chams-Davatchi C, Barikbin B, Shahram F, Nadji A, Moghaddassi M, Yousefi M, et al. Pimecrolimus versus placebo in genital aphthous ulcers of Behcet's disease: a randomized double-blind controlled trial. Int J Rheum Dis 2010; 13(3): 253-8.
Davatchi F. Behcet's Disease- Clinical manifestations and management. Proceedings of the Abu Dhabi Advanced Rheumatology Review Course (ADARRC); 2011 Oct 15-17; Abu Dhabi, United Arab Emirates.
Zouboulis CC. Extended venous thrombosis in Adamantiades-Behcet's disease. Eur J Dermatol 2004; 14(4): 268-71.
Kaneko Y, Tanaka K, Yoshizawa A, Yasuoka H, Suwa A, Satoh T, et al. Successful treatment of recurrent intracardiac thrombus in Behcet's disease with immunosuppressive therapy. Clin Exp Rheumatol 2005; 23(6): 885-7.
Ahn JK, Lee YS, Jeon CH, Koh EM, Cha HS. Treatment of venous thrombosis associated with Behcet's disease: immunosuppressive therapy alone versus immunosuppressive therapy plus anticoagulation. Clin Rheumatol 2008; 27(2): 201-5.
Rahil AI, Errayes M, Salem KM. Cerebral venous thrombosis as the initial presentation of Behcet's disease. Chang Gung Med J 2009; 32(2): 220-3.
Ketari JS, Chaaba H, Ben DB, Boussema F, Kochbati S, Cherif O, et al. Arterial involvement in Behcet's disease: a series of 7 cases. Tunis Med 2009; 87(9): 583-8.
Ramon I, De SK, Allard S, Ilsen B, Verfaillie G, Velkeniers B. Occurrence of pulmonary artery aneurysms and pulmonary artery thrombosis in a young man. Acta Clin Belg 2010; 65(6): 422-4.
